LSN2463359 is a positive allosteric modulator of the mGluR5,[2] which means it increases the activity of glutamate (an excitatory neurotransmitter) at this receptor.
Potential uses
A study has found that LSN2463359 and similar drugs can be used as a treatment to some aspects of cognitive deficits in schizophrenia.[3] Another study also mention that it could be used in the treatment of schizophrenia due to the potential interactions between NMDA receptors and mGluR5.[4]
↑Gilmour, Gary; Broad, Lisa M.; Wafford, Keith A.; Britton, Thomas; Colvin, Ellen M.; Fivush, Adam; Gastambide, Francois; Getman, Brian; Heinz, Beverly A.; McCarthy, Andrew P.; Prieto, Lourdes; Shanks, Elaine; Smith, Janice W.; Taboada, Lorena; Edgar, Dale M. (January 2013). "In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat". Neuropharmacology. 64: 224–239. doi:10.1016/j.neuropharm.2012.07.030. ISSN1873-7064. PMID22884720.